Watch MBIO. Know when insiders buy.
One email the day a filing lands. Free.
MBIO
MUSTANG BIO, INC.
0.54
+0.05 +10.20%
USD · close Sep 18
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
39
FLAG · shorts 39
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $13.5MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$3MNET CASH —52W 0.49 – 1.77SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$1.2M | −$1.1M | — | -0.16 | −$967K | — | — | Aug 5 |
| Q1 2026 · Mar 31 | — | — | — | −$1.1M | −$955K | — | -0.14 | −$1M | — | — | May 5 |
| Q4 2025 · Dec 31derived | — | — | — | −$670K | −$538K | — | -0.07 | −$1.7M | — | — | Mar 19 |
| Q3 2025 · Sep 30 | — | — | — | −$624K | −$468K | — | -0.07 | −$818K | — | — | Nov 7 |
| Q2 2025 · Jun 30 | — | — | — | −$885K | −$762K | — | -0.19 | −$1.3M | — | — | Aug 5 |
| Q1 2025 · Mar 31 | — | — | — | −$253K | −$153K | — | -0.05 | −$1.4M | — | — | May 5 |
| Q4 2024 · Dec 31derived | — | — | — | −$1M | −$952K | — | -6.39 | −$2M | $0 | −$2M | Mar 19 |
| Q3 2024 · Sep 30 | — | — | — | −$1.5M | −$1.4M | — | -1.96 | −$1.8M | $0 | −$1.8M | Nov 7 |
| Q2 2024 · Jun 30 | — | — | — | −$8.5M | −$8.2M | — | -18.36 | −$2.3M | — | — | Aug 8 |
| Q1 2024 · Mar 31 | — | — | — | −$5.2M | −$5.2M | — | -24.81 | −$5.3M | — | — | May 14 |
| Q4 2023 · Dec 31derived | — | — | — | −$8.7M | −$8.6M | — | -294.66 | −$7.3M | $30K | −$7.3M | Mar 28 |
| Q3 2023 · Sep 30 | — | — | — | −$10.3M | −$10.1M | — | -1.23 | −$12M | $0 | −$12M | Nov 8 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$2.4M | −$1.9M | — | -0.39 | −$5.3M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$16.2M | −$15.8M | — | -38.57 | −$11.4M | $0 | −$11.4M | — | — |
| FY2023 · to Dec 31 | — | — | −$49.3M | −$51.6M | — | -299.95 | −$49.5M | $64K | −$49.5M | — | — |
| FY2022 · to Dec 31 | — | — | −$76.2M | −$77.5M | — | -10.09 | −$65.1M | $2.7M | −$67.8M | — | — |
| FY2021 · to Dec 31 | — | — | −$66.7M | −$66.4M | — | -0.76 | −$53.7M | $4M | −$57.7M | — | — |
| FY2020 · to Dec 31 | — | — | −$56.8M | −$60M | — | -1.14 | −$37.3M | $1.9M | −$39.2M | — | — |
Every number comes from MUSTANG BIO, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.